|
Teravac HIV in chronic HIV-1. |
2011-08-10 |
CIGB |
|
THERESA-4 Study |
2011-10-25 |
CIGB |
|
Quimi-Hib® and Quimi-Hib(AlPO4) vaccines in an accelerated 6-10-14 weeks primary vaccination series |
2012-09-12 |
CIGB |
|
iorEPOCIM-Stroke-Phase I |
2012-09-17 |
CIMAB |
|
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection |
2012-10-12 |
CIGB |
|
D-004 in patients with Bening Prostatic Hyperplasia |
2013-01-04 |
CPN |
|
Intravenous CIGB-128-A in patients with brain tumors (BRATINC Study) |
2013-01-17 |
CIGB |
|
Safety with interferon in skin carcinomas (SCIENCE study) |
2013-01-30 |
CIGB |
|
Nimotuzumab for the treatment of high grade of malignancy tumors |
2013-02-01 |
CIMAB |
|
Interferon Combination in basal cell carcinoma (InCarbacel-V study) |
2013-02-01 |
CIGB |
|
Vidatox 30CH in advanced malignant tumors-Primary health care-Phase IV |
2013-05-21 |
LABIOFAM |
|
CIGB-247 vaccine in patients with solid malignant tumors, phase I, randomized. (CENTAURO-2 study) |
2013-06-06 |
CIGB |
|
Clinical Trial with the Outer Membrane Vesicles (OMV) Bivalent AW135 Anti meningocóccal Vacccine Candidate |
2013-06-19 |
FINLAY |
|
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX |
21/05/2021 |
CIM |
|
Nimotuzumab in COVID-19 |
21/05/2021 |
CIM |
|
VSSPs in renal carcinoma. |
21/06/2023 |
CIM |
|
Safety of Orally Administered Neutral pH Super Oxidation Electrolyzed Solution |
21/07/2023 |
SSA |
|
Itolizumab for Relapsing Remitting Multiple Sclerosis |
22/05/2015 |
CIM |
|
Safety and pharmacokinetics of CIGB-552 |
22/05/2015 |
CIGB |
|
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations |
22/05/2021 |
CIM |
